Received Feb 27, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | X1D141M | OT / RA |
received an extra dose of ipol with no reported adverse event; Initial information received on 26-Feb-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 9 years old male patient who received an extra dose of IPV (Vero) [IPOL], with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Hepatitis b vaccine (Hepatitis b vaccine); Measles vaccine, Mumps vaccine, Rubella vaccine (Mmr vaccin); and Pneumococcal vaccine conj 20v (CRM197) (Prevnar 20). On 25-Feb-2026, the patient received an extra 0.5mL of suspect IPV (Vero), Suspension for injection (lot X1D141M, expiry date 31-Oct-2026, strength standard and frequency once) via subcutaneous route in the right arm for Immunisation, with no reported adverse event (extra dose administered) (latency same day). It was reported "that they have a patient in their clinic yesterday, who received an extra dose of IPOL and Adacel. She asked if it would affect the patient in any way. She said that the patient was correctly administered with Pentacel on 20-Sep-2016, 04-Jan-2017, and13-May-2017. The patient received another DTAP and IPV (not PENTACEL)on 08-Nov-2021 which was also correctly administered. However, yesterday, he received an extra dose of IPOL and Adacel." Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Hepatitis b vaccine; Mmr vaccin; Prevnar 20